Sana Biotechnology ($SANA) claimed a long cash runway and a thriving clinical pipeline — but investors were blindsided when two flagship programs were scrapped and nearly a third of the workforce got cut. In this episode of Bulls & Betrayal, we dissect the timeline, the SEC filings, and the class action lawsuit that’s now accusing Sana of securities fraud.

Perfect for biotech investors, legal junkies, and financial sleuths, this episode delivers sharp analysis and storytelling with just the right dose of biotech drama.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

🎧 Subscribe & learn more at ZLK.com | Follow us @BullsBetrayal